Solu Therapeutics

Executive Summary

Solu Therapeutics is a clinical-stage biotechnology company pioneering a novel modality that links potent small molecules to effector antibodies via proprietary linker technology. Its platform enables the creation of Cytotoxicity Targeting Chimeras (CyTACs) and Therapeutic Index Control Targeting Chimeras (TicTACs), designed to unlock traditionally undruggable cell surface targets such as GPCRs and ion channels. The company is advancing a pipeline in oncology, immunology, and pain, with a lead asset currently in Phase 3 development. By combining the specificity of antibodies with the potency of small molecules, Solu aims to improve therapeutic index and address high-value targets that have been inaccessible to conventional biologics. The company is privately held and based in Cambridge, Massachusetts, with a strong intellectual property portfolio around its linker technology.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 Top-Line Data for Lead CyTAC Candidate60% success
• H2 2026Strategic Partnership or Licensing Deal for TicTAC Platform70% success
• 2026Initial Public Offering (IPO) or Series D Financing50% success